Clinical trials: Nonorganic Psychosis
- Condition Nonorganic Psychosis
- Funder type Industry (pharma, biotech, devices)
- Age group Children (under 18)
Hallucinations, Psychoses
Treatment of Hallucinosis/Psychosis in Parkinson's Disease by an Investigational Drug
The primary objective is to demonstrate that the investigational new drug, ACP-103, is well tolerated by, and will not worsen parkinsonism in, patients with Parkinson's disease and psychosis.
- Conditions
- Hallucinations, Psychoses, Parkinson's Disease
- Trial name
- NCT00087542
- Testing
- ACP-103
- Where
- 13 sites in United States
- Volunteers
- 60 people
- Sponsor
- ACADIA Pharmaceuticals Inc.
Acute Psychotic Symptoms
Quality Project to Evaluate and Validate the FAST-O Rating Scale
The purpose of this project is to test the reliability of the FAST-O Rating Scale in patients at acute wards or psychiatric intensive care units.
- Trial name
- FAST-O (NCT00913731)
- Where
- 5 sites in Sweden
- Volunteers
- 111 people
- Sponsor
- AstraZeneca
Schizophrenia, Psychotic Disorders
CAFE Comparison of Atypicals in First Episode of Psychosis
The purpose of this study is to compare the effectiveness, tolerability, and efficacy of the currently available atypical antipsychotic drugs olanzapine (2.5-20 mg/day), quetiapine (100-800 mg/day) and risperidone (0.5-4 mg/day)…
- Conditions
- Schizophrenia, Psychotic Disorders, Mental Health, Mental Disorders
- Trial name
- NCT00034892
- Testing
- Olanzapine, risperidone
- Where
- 26 sites in United States, Canada
- Sponsor
- AstraZeneca
Alzheimer's Disease, Dementia
A Study of the Effectiveness and Safety of Risperidone Versus Placebo in the Treatment of Patients With Hallucinations and Delusions Associated With Alzheimer's Disease
The purpose of this study is to assess the effectiveness and safety of risperidone (an antipsychotic medication) versus placebo for the treatment of patients with hallucinations and delusions associated with Alzheimer's disease.
- Trial name
- NCT00287742
- Testing
- risperidone
- Volunteers
- 33 people
- Sponsor
- Janssen Pharmaceutical K.K.
Schizophrenia
A Clinical Trial to Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With Schizophrenia
A clinical trial to study the efficacy and safety of an investigational drug in acutely psychotic people with schizophrenia. Participants in the study will either receive the drug being studied or a placebo.
- Trial name
- NCT04072354
- Testing
- SEP-363856 50mg, SEP-363856 75mg
- Where
- 53 sites in United States, Bulgaria and 4 more
- Volunteers
- 463 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Psychosis
Dose Finding of Quetiapine Fumarate 200mg vs 400mg in First Episode Psychosis
The purpose of this study is determine the minimal effective dose and the impact on: 1. treatment outcomes at 4, 12 and/or 48 weeks the treatment has required to treat patients experiencing the first psychotic episode 2.
- Trial name
- NCT00449397
- Testing
- Quetiapine Fumarate
- Where
- Australia
- Volunteers
- 150 people
- Sponsor
- AstraZeneca
Attention Deficit Disorder With Hyperactivity
A Study on Suicidality, Psychosis or Substance Abuse With Methylphenidate, Atomoxetine, Amphetamine/Dextroamphetamine or Lisdexamfetamine
The purpose of this study is to estimate the observed incidence of the health outcomes (suicide attempt or ideation, suicide ideation, suicide attempt, psychosis, and substance abuse) in a cohort of participants diagnosed with…
- Trial name
- NCT04132557
- Testing
- Methylphenidate, Lisdexamfetamine, Atomoxetine
- Where
- United States
- Volunteers
- 430,000 people
- Sponsor
- Janssen Research & Development, LLC
Psychosis
Adherence in Adolescents and Children Treated on Quetiapine
Observational study aimed to describe the adherence in a population of adolescents and children treated on quetiapine from a first psychotic episode whose more important secondary objective is to identify possible predictive…
- Trial name
- NCT00680888
- Volunteers
- 30 people
- Sponsor
- AstraZeneca
Schizophrenia, Psychotic Disorders
A Study of Risperidone in Combination With Lorazepam Compared With Standard Therapy for Emergency Treatment of Schizophrenic Patients
The purpose of the study is to show that risperidone (an antipsychotic medication) combined with lorazepam (an anti-anxiety medication) is more effective than conventional therapy administered by intramuscular injection for…
- Conditions
- Schizophrenia, Psychotic Disorders, Emergency Treatment
- Trial name
- NCT00249171
- Testing
- risperidone
- Volunteers
- 226 people
- Sponsor
- Janssen Pharmaceutica N.V., Belgium
Clinical High Risk for Psychosis (CHR)
A Study Exploring Changes in a Variety of Biomarkers Following Dosing With MT1988 in Participants at Clinical High Risk for Psychosis
The goal of this clinical trial is to learn how tests undertaken by people at high risk of developing psychosis (aged 17 to 30 years old) change when those people are given the study drug MT1988 daily for 8 weeks.
- Trial name
- NCT07226895
- Testing
- MT1988 Low Dose, MT1988 High Dose
- Where
- 15 sites in United States
- Volunteers
- 150 people
- Sponsor
- Monument Therapeutics Limited
Parkinson's Disease Psychosis
An Open-label Safety Study of Pimavanserin in Parkinson's Disease Patients
This is an open-label extension study to assess the long-term safety and tolerability of pimavanserin (ACP-103) in subjects with Parkinson's Disease Psychosis (PDP).
- Trial name
- NCT01518309
- Testing
- pimavanserin tartrate (ACP-103)
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- ACADIA Pharmaceuticals Inc.
Psychosis
A Follow up Safety Study of Patients Who Participated in Previous Studies of the Drug Org 24448 (Study P05719)(COMPLETED)
This is a safety study evaluating the subjects who participated in previous Organon trials of the drug Org 24448. Patients will undergo a Screening visit, 1 or 2 Evaluation visits, and a possible Follow-Up period.
- Trial name
- NCT00780585
- Testing
- SCH 900460
- Volunteers
- 95 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Velo-cardio-facial Syndrome, Psychosis
Metyrosine (Demser®) for the Treatment of Psychotic Disorders in Patients With Velocardiofacial Syndrome
This is an exploratory clinical investigation. The objectives of this study are to evaluate the safety, steady-state pharmacokinetics, and efficacy of metyrosine (Demser®) for the treatment of psychosis in patients with…
- Trial name
- NCT01127503
- Testing
- Metyrosine
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Bausch Health Americas, Inc.
Parkinson's Disease, Psychotic Disorders
Melperone (an Anti-Psychotic) in Patients With Psychosis Associated With Parkinson's Disease
The purpose of this study is to evaluate the safety and efficacy of three target doses of melperone compared to placebo in the treatment of psychosis associated with Parkinson's disease.
- Trial name
- NCT00125138
- Testing
- Melperone HCl
- Where
- 21 sites in United States, India and 1 more
- Volunteers
- 90 people
- Sponsor
- Lundbeck LLC
Schizophrenia, Schizophrenic Disorders
Open-label Study of Flexible-dose Paliperidone ER (Extended Release) to Treat Adolescent Schizophrenia.
The purpose of this open-label study is to evaluate the long-term (6-month) safety and tolerability of extended-release paliperidone, an atypical antipsychotic, given in flexible dosages to adolescents with schizophrenia.
- Conditions
- Schizophrenia, Schizophrenic Disorders, Psychotic Disorders, Dementia Praecox
- Trial name
- NCT00488319
- Testing
- Paliperidone ER
- Where
- 53 sites in United States, Belgium and 9 more
- Volunteers
- 400 people
- Sponsor
- Janssen Research & Development, LLC
Schizophrenia
A Pilot Study of the Use of Risperidone Long Acting Injectable in the Treatment of Patients With Recent Onset Psychosis
The purpose of the study is to assess the effectiveness and safety of long-acting injectable risperidone in the treatment of patients in the early stage of psychosis
- Trial name
- NCT00216580
- Testing
- Risperidone, long-acting injectable
- Volunteers
- 50 people
- Sponsor
- Janssen Pharmaceutica N.V., Belgium
Psychotic Disorders
This Study Tests Whether BI 409306 Prevents Patients With a Specific Type of Mental Illness (Attenuated Psychosis Syndrome) From Becoming Worse. This Study Looks at How Well Patients Tolerate the Medicine and How Effective it is Over 1 Year
This is a study in people between 16 and 30 years of age who have a specific type of mental illness called attenuated psychosis syndrome (APS).
- Trial name
- NCT03230097
- Testing
- BI 409306
- Where
- 33 sites in United States, Canada and 2 more
- Volunteers
- 50 people
- Sponsor
- Boehringer Ingelheim